Viewpoint - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Viewpoint

How to Manage Effective Leadership when Change is the Only Constant

November 2, 2012

Pharmaceutical Technology

A disciplined approach to changing behavior can achieve change agility.

FDA and the Importance of Confidentiality

October 2, 2012

Pharmaceutical Technology

Recent news stories have reported that FDA scientists have been suspected of leaking confidential, commercial, and trade secret information to the media.

Technology Transfer: Protecting the True Public Interest

September 2, 2012

Pharmaceutical Technology

Ties between the biotechnology industry and university research are crucial.

Weighing Access and Affordability

September 1, 2012

Pharmaceutical Technology

Policymakers must balance fundamental issues involving access to medicines and pricing.

Enactment of FDA Reform Act Improves Drug Safety

August 2, 2012

Pharmaceutical Technology

New law provides FDA with the resources it needs to safeguard drug supply chain.

Requirements for Electronic Records Contained in 21 CFR 211

July 18, 2012

Pharmaceutical Technology

The author discusses the regulatory requirements for electronic records contained in Title 21 CFR Part 211 and how they overlap with the requirements set forth in Title 21 CFR Part 11.

Future Innovation

July 2, 2012
Pharmaceutical Technology

Presidents of leading associations offer views on the industry's future.

Biosimilar Developers Face a Reference-Product Dilemma

June 2, 2012

Pharmaceutical Technology

Does global development have to entail multiple comparability studies?

The Growing Orphan-Drug Paradigm

May 2, 2012

Pharmaceutical Technology

How niche strategies can offer mainstream potential for biopharmaceutical companies.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Click here